OBJECTIVE: In recent years, stereotactic radiosurgery has been growing in p
opularity as a treatment modality for metastatic disease to the brain. The
technique has advantages of reduced cost and low morbidity compared with op
en surgical treatment. Furthermore, it avoids the potential cognitive side
effects of fractionated whole-brain radiotherapy. We undertook this study t
o determine the usefulness of adjuvant radiation therapy and to determine p
rognostic factors in patients treated with stereotactic radiosurgery.
METHODS: We reviewed our series of patients with metastatic tumors treated
using gamma knife stereotactic radiosurgery from August 1994 to February 19
99. Nonparametric methods were used to compare treatment subgroups by demog
raphic features including age, Karnofsky Performance Scale score, diagnosis
, and systemic disease status. Univariate and multivariate analyses of surv
ival and freedom from progression were performed using Kaplan-Meier and Cox
proportional hazards regression techniques.
RESULTS: This study included 190 patients harboring 431 lesions who were tr
eated in 263 treatment sessions. The median follow-up after radiosurgery wa
s 36 weeks for all patients. The median actuarial survival from the time of
radiosurgery in all patients was 34 weeks. When patients were stratified a
ccording to tumor histology, those without melanoma had a median survival o
f 39 weeks, and those with melanoma had a median survival of 28 weeks. The
cause of death could be determined in 122 (92 %) of the patients known to h
ave died during the data capture period. For patients harboring melanoma, d
eath was attributable to systemic disease in 31 (47%), to central nervous s
ystem-related processes in 29 (44%), and to unknown causes in 6 (9%). For n
on-melanoma patients, death was attributable to systemic disease in 45 (68%
), to central nervous system-related processes in 17 (26%), and to unknown
causes in 4 (6%). Significantly improved survival (P = 0.002) was observed
in patients with controlled systemic disease. No significant difference in
survival could be ascertained for patients presenting with up to lour lesio
ns, although patients with a total tumor volume greater than 9 cc had short
ened survival. No survival benefit could be demonstrated for whole-brain ra
diotherapy administered either concomitantly or after radiosurgery.
CONCLUSION: Factors correlated with significantly improved survival include
d controlled systemic disease and non-melanoma histology. We found no signi
ficant survival benefit that could be discerned from adjuvant whole-brain r
adiotherapy in this patient group.